{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:37:29Z","timestamp":1648726649817},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T00:00:00Z","timestamp":1287014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s10620-010-1435-7","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T03:01:18Z","timestamp":1287025278000},"page":"3013-3015","source":"Crossref","is-referenced-by-count":1,"title":["Methotrexate for Primary Biliary Cirrhosis: Who Is to Be Trusted?"],"prefix":"10.1007","volume":"55","author":[{"given":"Carlo","family":"Selmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Podda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,14]]},"reference":[{"key":"1435_CR1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","volume":"127","author":"C Selmi","year":"2004","unstructured":"Selmi C, Mayo MJ, Bach N, et\u00a0al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127:485\u2013492.","journal-title":"Gastroenterology"},{"key":"1435_CR2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","volume":"42","author":"X Liu","year":"2010","unstructured":"Liu X, Invernizzi P, Lu Y, et\u00a0al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42:658\u2013660.","journal-title":"Nat Genet"},{"key":"1435_CR3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.it.2009.05.006","volume":"30","author":"C Selmi","year":"2009","unstructured":"Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 2009;30:415\u2013420.","journal-title":"Trends Immunol"},{"key":"1435_CR4","doi-asserted-by":"crossref","unstructured":"Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2008:CD000551.","DOI":"10.1002\/14651858.CD000551.pub2"},{"key":"1435_CR5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon RE, Lindor KD, Cauch-Dudek K, et\u00a0al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884\u2013890.","journal-title":"Gastroenterology"},{"key":"1435_CR6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","volume":"36","author":"G Paumgartner","year":"2002","unstructured":"Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525\u2013531.","journal-title":"Hepatology"},{"key":"1435_CR7","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","volume":"42","author":"B Combes","year":"2005","unstructured":"Combes B, Emerson SS, Flye NL, et\u00a0al. Methotrexate (mtx) plus ursodeoxycholic acid (udca) in the treatment of primary biliary cirrhosis. Hepatology. 2005;42:1184\u20131193.","journal-title":"Hepatology"},{"key":"1435_CR8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","volume":"41","author":"H Rautiainen","year":"2005","unstructured":"Rautiainen H, Karkkainen P, Karvonen AL, et\u00a0al. Budesonide combined with udca to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005;41:747\u2013752.","journal-title":"Hepatology"},{"key":"1435_CR9","first-page":"550A","volume":"46","author":"RP Myers","year":"2007","unstructured":"Myers RP, Shaheen AA, Swain MG, et\u00a0al. Rituximab for primary biliary cirrhosis (pbc) refractory to ursodeoxycholic acid (udca). Hepatology. 2007;46:550A.","journal-title":"Hepatology"},{"key":"1435_CR10","doi-asserted-by":"crossref","unstructured":"Mason A, Luketic V, K.D. L, et\u00a0al. Farnesoid-x receptor agonists: A new class of drugs for the treatment of pbc? An international study evaluating the addition of int-747 (obeticholic acid) to ursodeoxycholic acid. J Hepatol. 2010;52:S1.","DOI":"10.1016\/S0168-8278(10)60004-9"},{"key":"1435_CR11","doi-asserted-by":"crossref","unstructured":"Kaplan MM, Bonder A, Ruthazer R, Bonis PAL. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci. 2010. doi: 10.1007\/s10620-010-1291-5 .","DOI":"10.1007\/s10620-010-1291-5"},{"key":"1435_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cld.2008.02.012","volume":"12","author":"MJ Mayo","year":"2008","unstructured":"Mayo MJ. Natural history of primary biliary cirrhosis. Clin Liver Dis. 2008;12:277\u2013288. (viii).","journal-title":"Clin Liver Dis"},{"key":"1435_CR13","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/0016-5085(91)90085-Y","volume":"101","author":"MM Kaplan","year":"1991","unstructured":"Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology. 1991;101:1332\u20131338.","journal-title":"Gastroenterology"},{"key":"1435_CR14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","volume":"117","author":"MT Hendrickse","year":"1999","unstructured":"Hendrickse MT, Rigney E, Giaffer MH, et\u00a0al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology. 1999;117:400\u2013407.","journal-title":"Gastroenterology"},{"key":"1435_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(97)80294-2","volume":"27","author":"A Gonzalez-Koch","year":"1997","unstructured":"Gonzalez-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol. 1997;27:143\u2013149.","journal-title":"J Hepatol"},{"key":"1435_CR16","doi-asserted-by":"crossref","unstructured":"Giljaca V, Poropat G, Stimac D, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2010;5:CD004385.","DOI":"10.1002\/14651858.CD004385.pub3"},{"key":"1435_CR17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouilleres","year":"1998","unstructured":"Chazouilleres O, Wendum D, Serfaty L, et\u00a0al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296\u2013301.","journal-title":"Hepatology"},{"key":"1435_CR18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.7326\/0003-4819-99-4-544","volume":"99","author":"AR Feinstein","year":"1983","unstructured":"Feinstein AR. An additional basic science for clinical medicine: Ii. The limitations of randomized trials. Ann Intern Med. 1983;99:544\u2013550.","journal-title":"Ann Intern Med"},{"key":"1435_CR19","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3085","volume":"12","author":"E Quintin","year":"2010","unstructured":"Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010;12:R143.","journal-title":"Arthritis Res Ther"},{"key":"1435_CR20","doi-asserted-by":"crossref","unstructured":"Selmi C, De Santis M, Gershwin ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther. 2010 (in press).","DOI":"10.1186\/ar3319"},{"key":"1435_CR21","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.23132","volume":"50","author":"K Yoshida","year":"2009","unstructured":"Yoshida K, Yang GX, Zhang W, et\u00a0al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type ii mice. Hepatology. 2009;50:1494\u20131500.","journal-title":"Hepatology"},{"key":"1435_CR22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaut.2009.02.022","volume":"32","author":"KA Padgett","year":"2009","unstructured":"Padgett KA, Lan RY, Leung PC, et\u00a0al. Primary biliary cirrhosis is associated with altered hepatic microrna expression. J Autoimmun. 2009;32:246\u2013253.","journal-title":"J Autoimmun"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-010-1435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-010-1435-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-010-1435-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T08:56:54Z","timestamp":1559725014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-010-1435-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,14]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1007\/s10620-010-1435-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,14]]}}}